Novo Nordisk (NYSE:NVO), the Danish pharmaceutical company, has seen a 500% increase in the amount of the company on loan since early March - from 2% then to 10% now. The company's share price has fallen from 310DKK ($55) to 270DKK ($48) between early February and last week, with the price rebounding slightly from 250DKK ($44) in the past few days. Utilisation, relatively, is not particularly high at 25%, which means that it is still fairly easy to borrow this stock. On March 19th there were 3.5m shares traded compared to the three-month average of 1.5m.
Click to enlarge: